

Ref: FOI/GS/ID 9548

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone, Kent
ME16 9QQ
Email: mtw-tr.foiadmin@nhs.net
www.mtw.nhs.uk

29 November 2024

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to the treatment of certain types of cancer.

You asked: All questions are shown as received by the Trust.

Q1. How many early-stage (non-metastatic or Stages 1-3) non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:

- a. Atezolizumab (Tecentriq)*
- b. Durvalumab (Imfinzi)*
- c. Nivolumab (Opdivo)*
- d. Pembrolizumab (Keytruda)*
- e. Chemotherapy*
- f. Radiotherapy*
- g. Chemotherapy AND Radiotherapy*
- h. Osimertinib*

Q2. How many patients were treated in the past 3 months for gastric and gastro-oesophageal junction cancer (any stage) with:

- a. CAPOX (Capecitabine with Oxaliplatin)*
- b. FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin)*
- c. Lonsurf (Trifluridine - tipiracil)*
- d. Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)*
- e. Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)*
- f. Any other systemic anti-cancer therapy*
- g. Palliative care only*
- h. Zolbetuximab (Vyloy)*

Trust response:

Q1.

a. 4

b. 3

c. 1

d. 17

e. 20

f. 29

g. 10

h. 14

Q2.

a. 2

b. 3

c. 0

d. 3

e. 2

f. 31

g. 2

h. 0